Therapeutic Response

BRCA2 oncogenic variants status confers therapeutic sensitivity to Abiraterone acetate in combination with Niraparib and Prednisone in patients with Prostate Adenocarcinoma.

Statements

Source and description
Akeega (abiraterone acetate and niraparib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.
Akeega (abiraterone acetate and niraparib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.
Akeega (abiraterone acetate and niraparib) [product monograph]. HC. Health Canada approved niraparib and abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (mCRPC), who are asymptomatic or mildly symptomatic, and in whom chemotherapy is not clinically indicated.